Stockreport

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF -Up to $24 million in upfront and milestone payments, plus royalties--Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring [Read more]